Holders — by stockHoldings — by fund

GILEAD SCIENCES, INC.

Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0000882095

$1.65B

disclosed book value

positions

58.8%

largest position share

Positions, as of 2026-06-30

top 5 of 5 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held

#	Issuer	Shares	Value	% of book
1	RCUSArcus Biosciences Inc.	31.4M	$968.8M	58.8%
2	LKFTLakefront Biotherapeutics	16.7M	$500.2M	30.3%
3	ASMBAssembly Biosciences Inc.	5.0M	$136.8M	8.3%
4	KYTXKyverna Therapeutics Inc.	4.1M	$36.8M	2.2%
5	Xilio Therapeutics Inc.	650,389	$6.2M	0.4%

Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.